Immune checkpoint inhibitors, particularly anti-PD-1/PD-L1 antibodies, have transformed cancer treatment by enabling clinical remission in advanced tumors such as non-small cell lung cancer, melanoma, and ovarian cancer [19,20,21,22,23,24,25]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.